Researchers announced promising results for a new cancer treatment called ODM-212, which targets specific tumors linked to the Hippo signaling pathway. Presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, the early findings suggest that ODM-212 is well-tolerated by patients with advanced solid tumors, with the most common side effect being proteinuria, or protein in the urine.

This research could be significant for individuals battling difficult-to-treat cancers such as mesothelioma and epithelioid hemangioendothelioma (EHE). In the study, 15.6% of participants experienced a treatment response, with higher rates observed in those with mesothelioma (27.8% response rate) and EHE (22.2% response rate). These results indicate that ODM-212 might offer a new option for people whose cancer has progressed despite existing treatments.

The current evidence comes from a Phase 1/2 clinical trial involving patients with various solid tumors. While these initial results are encouraging, they are still early-stage findings. The ongoing Phase 2 trial will include up to 300 patients and aims to further assess the safety and effectiveness of ODM-212. As the research progresses, it may provide more definitive insights into how this treatment can improve outcomes for those facing challenging cancer diagnoses.

Source: globenewswire.com